Test BEY1107 plus gemcitabine for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early study tests whether BEY1107 given alone or with gemcitabine can be used safely and may help shrink pancreatic cancer tumors. It mainly looks at safety, side effects, and signs of effectiveness in people with pancreatic ductal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic ductal adenocarcinoma (or an undifferentiated type) confirmed by tissue or cell test
- You have at least one measurable tumor spot on scans
- Your general activity level is ECOG 0 to 2 (you can do self-care; limited activity is OK)
- Your expected lifespan is more than 12 weeks
- Your blood counts and kidney/liver tests are adequate at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
This trial tests a new drug called MRG003 combined with gemcitabine for people with advanced pancreatic cancer that has stopped responding to or cannot tolerate initial treatment. It aims to see if the combination can shrink tumors or slow the disease.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This Phase 2 study tests whether adding BLEX 404 to gemcitabine can improve outcomes for people with inoperable or metastatic pancreatic cancer. It may help shrink the cancer or slow its growth by combining two treatments.
Hear when a new Locally Advanced or Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.